Table 2. Place of eclamptic fit and proportion of facilities with magnesium sulfate available on average over trial duration.
| Site | Total n | n (percent of eclampsia cases) | Mean magnesium sulfate availability over trial duration (%) | ||
|---|---|---|---|---|---|
| Central referral facility | Peripheral facility | Community | |||
| All sites | 2,692 | 839 (31.2%) | 643 (23.9%) | 1,210 (44.9%) | 74.7% |
| Ethiopia | 203 | 57 (28.1%) | 67 (33.0%) | 79 (38.9%) | 87.4% |
| Haiti | 125 | 52 (41.6%) | 16 (12.8%) | 57 (45.6%) | 25.0% |
| India | 85 | 27 (31.8%) | 4 (4.7%) | 54 (63.5%) | 95.4% |
| Malawi | 666 | 242 (36.3%) | 219 (32.9%) | 205 (30.8%) | 100.0% |
| Sierra Leone | 338 | 20 (5.9%) | 95 (28.1%) | 223 (66.0%) | 41.4% |
| Uganda Centre 1 | 559 | 161 (28.8%) | 125 (22.4%) | 273 (48.8%) | 61.5% |
| Uganda Centre 2 | 167 | 142 (85.0%) | 17 (10.2%) | 8 (4.8%) | 78.6% |
| Zambia Centre 1 | 242 | 34 (14.0%) | 61 (25.2%) | 147 (60.7%) | 79.8% |
| Zambia Centre 2 | 89 | 38 (42.7%) | 13 (14.6%) | 38 (42.7%) | 77.4% |
| Zimbabwe | 218 | 66 (30.3%) | 26 (11.9%) | 126 (57.8%) | 100.0% |